Ventyx Biosciences (VTYX) Lead Product Candidate Failure Case

• $VTYX stockholder filed a claim vs. Ventyx Biosciences for purportedly overpromising the potential success of plaque psoriasis candidate during the IPO in 2021.

• In November 2022, disappointing Phase 2 SERENITY Trial results caused $VTYX to fall 80%, losing $672 million in shareholder value.

On November 6, 2023, Ventyx Biosciences (VTYX) announced the results of the Phase 2 SERENITY Trial, disclosing that "although the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support the advancement of VTX958 in plaque psoriasis."

Based on these results, Ventyx announced that it "will terminate ongoing activities in the Phase 2 plaque psoriasis trial effective immediately" and "terminate the ongoing Phase 2 trial of VTX958 in psoriatic arthritis."

On this news, $VTYX fell 80.6% and lost over $672 million of its market capitalization, seriously damaging investors.

Then, on November 22, 2023, Ventyx disclosed that its President & CMO, William J. Sandborn, would cease to serve in those roles.

$VTYX is trading at $8.5 per share, well below the $16 IPO price.

Considering all the facts, investors have reasons to suspect Ventyx and its Leader of overpromising the potential success of the lead product candidate during the IPO in 2021.

The first $VTYX stockholder filed a claim vs. Ventyx over misleading IPO in S.D. California court.